A Phase 2 interventional study of Islatravir and Placebo to Islatravir in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 26 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-29.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the safety, tolerability, antiretroviral activity, and pharmacokinetics of 3 doses of islatravir (MK-8591) in combination with doravirine (DOR) and lamivudine (3TC) administered to antiretroviral treatment-naïve adult participants with human immunodeficiency virus type 1 (HIV-1) infection.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be treated once daily (QD) with 0.25 mg islatravir, 100 mg DOR, 300 mg 3TC, and placebo to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to DOR/3TC/TDF may be discontinued. Around Week 60, participants may be switched to a selected open label dose of islatravir and DOR 100 mg QD and continue treatment until Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
Drug: Islatravir · Drug: Doravirine · Drug: Lamivudine · Drug: Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate · Drug: Doravirine/Islatravir
Participants will be treated QD with 0.75 mg islatravir, 100 mg DOR, 300 mg 3TC, and placebo to DOR/3TC/TDF for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to DOR/3TC/TDF may be discontinued. Around Week 60, participants may be switched to a selected open label dose of islatravir and DOR 100 mg QD and will continue treatment until Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
Drug: Islatravir · Drug: Doravirine · Drug: Lamivudine · Drug: Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate · Drug: Doravirine/Islatravir
Participants will be treated QD with 2.25 mg islatravir, 100 mg DOR, 300 mg 3TC, and placebo to DOR/3TC/TDF for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to DOR/3TC/TDF may be discontinued. Around Week 60, participants may be switched to a selected open label dose of islatravir and DOR 100 mg QD and will continue treatment until Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
Drug: Islatravir · Drug: Doravirine · Drug: Lamivudine · Drug: Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate · Drug: Doravirine/Islatravir
Participants will be treated QD with placebo to islatravir, placebo to DOR, placebo to 3TC, and a fixed dose combination of DOR/3TC/TDF consisting of 100 mg DOR + 300 mg 3TC + 300 mg TDF for a minimum of 24 weeks. Between week 24 through week 52 placebo treatments may be discontinued and participants will receive only DOR/3TC/TDF QD open label up to Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
Drug: Placebo to Islatravir · Drug: Placebo to Doravirine · Drug: Placebo to Lamivudine · Drug: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate · Drug: Doravirine/Islatravir
Islatravir at 0.25 mg, 0.75 mg or 2.25 mg is orally administered QD in capsule form for up to 52 weeks. After Week 60 a selected open label dose may be administered.
Also known as: MK-8591
Placebo to islatravir is orally administered QD in capsule form for up to 52 weeks
Doravirine 100 mg is orally administered QD in tablet form for up to 144 weeks
Also known as: MK-1439
Placebo to Doravirine is orally administered QD in tablet form for up to 52 weeks
Lamivudine 300 mg is orally administered QD in tablet form for up to 52 weeks
Also known as: 3TC
Placebo to Lamivudine is orally administered QD in tablet form for up to 52 weeks
Drug page: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
Fixed dose combination of 100 mg doravirine + 300 mg lamivudine + 300 mg tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 144 weeks.
Also known as: MK-1439A
Placebo to doravirine/lamivudine/tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 52 weeks
Drug pages: Doravirine · Islatravir
Fixed dose combination of islatravir 0.75 mg/doravirine 100 mg orally administered QD in tablet form for 48 weeks
Also known as: MK-8591A
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 24
Blood samples were collected and plasma human immunodeficiency virus 1 (HIV-1) ribonucleic acid (RNA) were quantified using a real time polymerase chain reaction (PCR) assay with a lower limit of detection of 40 copies/mL. Missing values were counted as failure.
Time frame: Week 24
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48
Blood samples were collected and plasma HIV-1 RNA were quantified using a real time PCR assay with a lower limit of detection of 40 copies/mL. Missing values were counted as failure.
Time frame: Week 48
Number of Participants Experiencing Adverse Events (AEs) up to Week 144
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.
Time frame: Up to 144 weeks
Number of Participants Discontinuing Study Drug Due to AEs up to Week 144
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.
Time frame: Up to 144 weeks
Percentage of Participants With HIV-1 RNA <50 Copies/mL up to 24 Weeks After 3TC and Placebo Are Discontinued From the Regimen
Blood samples were collected and plasma HIV-1 RNA were quantified using a real time PCR assay with a lower limit of detection of 40 copies/mL, and missing values were counted as failure. 3TC and placebo are discontinued from the regimen from Week 24 up to Week 52.
Time frame: Up to 24 weeks after 3TC and Placebo are discontinued from the regimen (up to approximately 60 weeks after initiating treatment)
Percentage of Participants With HIV-1 RNA <50 Copies/mL up to 48 Weeks After 3TC and Placebo Are Discontinued From the Regimen
Blood samples were collected and plasma HIV-1 RNA were quantified using a real time PCR assay with a lower limit of detection of 40 copies/mL, and missing values were counted as failure. 3TC and placebo are discontinued from the regimen from Week 24 up to Week 52.
Time frame: Up to 48 weeks
Percentage of Participants With HIV-1 RNA <50 Copies/mL up to 48 Weeks After Starting Open-label Doravirine/Islatravir Regimen (Part 4)
Blood samples were collected and plasma HIV-1 RNA were quantified using a real time PCR assay with a lower limit of detection of 40 copies/mL. Missing values were counted as failure. The percentage of participants with HIV-1 RNA \<50 copies in Part 4 are reported.
Time frame: Up to Week 192
Change From Baseline in Mature T-helper (CD4+ T)-Cell Count at Week 24
Blood samples were collected and cluster of differentiation (CD4)+ T-cell counts were performed, where baseline measurements are defined as the Day 1 value, and baseline values were carried forward for participants who discontinue due to lack of efficacy. Post-baseline data were collected after the first dose of study medication through 14 days after the last dose of study medication.
Time frame: Baseline and Week 24
Change From Baseline in CD4+ T-cell Count at Week 48
Blood samples were collected and CD4+ T-cell counts were performed, where baseline measurements are defined as the Day 1 value, and baseline values were carried forward for participants who discontinue due to lack of efficacy. Post-baseline data were collected after the first dose of study medication through 14 days after the last dose of study medication.
Time frame: Baseline and Week 48
Change From Baseline in CD4+ T-cell Count at Week 96
Blood samples were collected and CD4+ T-cell counts were performed, where baseline measurements are defined as the Day 1 value, and baseline values were carried forward for participants who discontinue due to lack of efficacy. Post-baseline data were collected after the first dose of study medication through 14 days after the last dose of study medication.
Time frame: Baseline and Week 96
Change From Baseline in CD4+ T-cell Count at Week 144
Blood samples were collected and CD4+ T-cell counts were performed, where baseline measurements are defined as the Day 1 value, and baseline values were carried forward for participants who discontinue due to lack of efficacy. Post-baseline data were collected after the first dose of study medication through 14 days after the last dose of study medication.
Time frame: Baseline and Week 144
Change From Baseline in CD4+ T-cell Count at Week 192 (Part 4)
Blood samples were collected and CD4+ T-cell counts were performed, where baseline measurements are defined as the Week 144 value. The change from baseline in CD4+ T-cell count at Week 192 (Part 4) are reported.
Time frame: Baseline and Week 192
Number of Participants Experiencing AEs Through 24 Weeks After 3TC and Placebo Are Discontinued From the Regimen
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. 3TC and placebo are discontinued from the regimen from Week 24 up to Week 52.
Time frame: Up to 24 weeks
Number of Participants Discontinuing Study Drug Due to AEs Through 24 Weeks After 3TC and Placebo Are Discontinued From the Regimen
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. 3TC and placebo are discontinued from the regimen from Week 24 up to Week 52.
Time frame: Up to 24 weeks
Number of Participants Experiencing AEs From Week 96 Through Study Duration
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.
Time frame: Week 96 up to Week 192
Number of Participants Discontinuing Study Drug Due to AEs From Week 96 Through Study Duration
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.
Time frame: Week 96 up to Week 192
Number of Participants Experiencing AEs During Open Label Doravirine/Islatravir Treatment After Week 144 up to Week 192 (Part 4)
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. The number of participants who experienced AEs during Part 4 are reported.
Time frame: Week 144 up to Week 192
Number of Participants Discontinuing Study Drug Due to AEs During Open Label Doravirine/Islatravir Treatment After Week 144 up to Week 192 (Part 4)
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. The number of participants who discontinued the study drug due to AEs in Part 4 are reported.
Time frame: Week 144 up to Week 192
Treatment-naïve participants ≥18 years of age with human immunodeficiency virus type 1 (HIV-1) were enrolled in this study.
| Milestone | Islatravir 0.25 mg | Islatravir 0.75 mg | Islatravir 2.25 mg | DOR/3TC/TDF |
|---|---|---|---|---|
| Started | 31 | 30 | 31 | 31 |
| Treated | 29 | 30 | 31 | 31 |
| Completed | 20 | 24 | 19 | 24 |
| Not completed | 11 | 6 | 12 | 7 |
| Withdrew: Death | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 3 | 5 | 1 |
| Withdrew: Physician decision | 4 | 2 | 5 | 4 |
| Withdrew: Screen failure | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 5 | 1 | 2 | 1 |
Blood samples were collected and plasma human immunodeficiency virus 1 (HIV-1) ribonucleic acid (RNA) were quantified using a real time polymerase chain reaction (PCR) assay with a lower limit of detection of 40 copies/mL. Missing values were counted as failure.
| Percentage of participants | Islatravir 0.25 mg | Islatravir 0.75 mg | Islatravir 2.25 mg | DOR/3TC/TDF |
|---|---|---|---|---|
| Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 24 | 93.1 | 100.0 | 90.3 | 90.3 |
Blood samples were collected and plasma HIV-1 RNA were quantified using a real time PCR assay with a lower limit of detection of 40 copies/mL. Missing values were counted as failure.
| Percentage of participants | Islatravir 0.25 mg | Islatravir 0.75 mg | Islatravir 2.25 mg | DOR/3TC/TDF |
|---|---|---|---|---|
| Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48 | 89.7 | 90.0 | 77.4 | 83.9 |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.
| Participants | Islatravir 0.25 mg | Islatravir 0.75 mg | Islatravir 2.25 mg | DOR/3TC/TDF |
|---|---|---|---|---|
| Number of Participants Experiencing Adverse Events (AEs) up to Week 144 | 26 | 27 | 24 | 27 |
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.
| Participants | Islatravir 0.25 mg | Islatravir 0.75 mg | Islatravir 2.25 mg | DOR/3TC/TDF |
|---|---|---|---|---|
| Number of Participants Discontinuing Study Drug Due to AEs up to Week 144 | 1 | 0 | 2 | 1 |
Blood samples were collected and plasma HIV-1 RNA were quantified using a real time PCR assay with a lower limit of detection of 40 copies/mL, and missing values were counted as failure. 3TC and placebo are discontinued from the regimen from Week 24 up to Week 52.
| Percentage of participants | Islatravir 0.25 mg | Islatravir 0.75 mg | Islatravir 2.25 mg | DOR/3TC/TDF |
|---|---|---|---|---|
| Percentage of Participants With HIV-1 RNA <50 Copies/mL up to 24 Weeks After 3TC and Placebo Are Discontinued From the Regimen | 86.2 | 90.0 | 88.9 | 96.4 |
Blood samples were collected and plasma HIV-1 RNA were quantified using a real time PCR assay with a lower limit of detection of 40 copies/mL, and missing values were counted as failure. 3TC and placebo are discontinued from the regimen from Week 24 up to Week 52.
| Percentage of participants | Islatravir 0.25 mg | Islatravir 0.75 mg | Islatravir 2.25 mg | DOR/3TC/TDF |
|---|---|---|---|---|
| Percentage of Participants With HIV-1 RNA <50 Copies/mL up to 48 Weeks After 3TC and Placebo Are Discontinued From the Regimen | 62.1 | 56.7 | 59.3 | 60.7 |
Blood samples were collected and plasma HIV-1 RNA were quantified using a real time PCR assay with a lower limit of detection of 40 copies/mL. Missing values were counted as failure. The percentage of participants with HIV-1 RNA \<50 copies in Part 4 are reported.
| Percentage of participants | DOR/ISL Continued (Part 4) | DOR/ISL Switch (Part 4) |
|---|---|---|
| Percentage of Participants With HIV-1 RNA <50 Copies/mL up to 48 Weeks After Starting Open-label Doravirine/Islatravir Regimen (Part 4) | 85.1 | 95.5 |
Blood samples were collected and cluster of differentiation (CD4)+ T-cell counts were performed, where baseline measurements are defined as the Day 1 value, and baseline values were carried forward for participants who discontinue due to lack of efficacy. Post-baseline data were collected after the first dose of study medication through 14 days after the last dose of study medication.
| cells/mm^3 | Islatravir 0.25 mg | Islatravir 0.75 mg | Islatravir 2.25 mg | DOR/3TC/TDF |
|---|---|---|---|---|
| Change From Baseline in Mature T-helper (CD4+ T)-Cell Count at Week 24 | 220.5 (170.3 to 270.8) | 192.8 (117.9 to 267.7) | 142.9 (89.9 to 196.0) | 142.1 (105.7 to 178.5) |
Blood samples were collected and CD4+ T-cell counts were performed, where baseline measurements are defined as the Day 1 value, and baseline values were carried forward for participants who discontinue due to lack of efficacy. Post-baseline data were collected after the first dose of study medication through 14 days after the last dose of study medication.
| cells/mm^3 | Islatravir 0.25 mg | Islatravir 0.75 mg | Islatravir 2.25 mg | DOR/3TC/TDF |
|---|---|---|---|---|
| Change From Baseline in CD4+ T-cell Count at Week 48 | 182.0 (119.6 to 244.5) | 183.0 (124.7 to 241.2) | 100.7 (25.0 to 176.3) | 181.4 (137.2 to 225.6) |
Blood samples were collected and CD4+ T-cell counts were performed, where baseline measurements are defined as the Day 1 value, and baseline values were carried forward for participants who discontinue due to lack of efficacy. Post-baseline data were collected after the first dose of study medication through 14 days after the last dose of study medication.
| cells/mm^3 | Islatravir 0.25 mg | Islatravir 0.75 mg | Islatravir 2.25 mg | DOR/3TC/TDF |
|---|---|---|---|---|
| Change From Baseline in CD4+ T-cell Count at Week 96 | 243.4 (165.5 to 321.3) | 161.3 (90.2 to 232.4) | 136.5 (57.0 to 216.0) | 268.9 (188.5 to 349.3) |
Blood samples were collected and CD4+ T-cell counts were performed, where baseline measurements are defined as the Day 1 value, and baseline values were carried forward for participants who discontinue due to lack of efficacy. Post-baseline data were collected after the first dose of study medication through 14 days after the last dose of study medication.
| cells/mm^3 | Islatravir 0.25 mg | Islatravir 0.75 mg | Islatravir 2.25 mg | DOR/3TC/TDF |
|---|---|---|---|---|
| Change From Baseline in CD4+ T-cell Count at Week 144 | 204.4 (102.0 to 306.7) | 209.0 (111.5 to 306.6) | 162.9 (70.2 to 255.5) | 270.0 (183.2 to 356.8) |
Blood samples were collected and CD4+ T-cell counts were performed, where baseline measurements are defined as the Week 144 value. The change from baseline in CD4+ T-cell count at Week 192 (Part 4) are reported.
| cells/mm^3 | DOR/ISL Continued (Part 4) | DOR/ISL Switch (Part 4) |
|---|---|---|
| Change From Baseline in CD4+ T-cell Count at Week 192 (Part 4) | 3.8 (-1.9 to 9.5) | -3.4 (-12.0 to 5.2) |
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. 3TC and placebo are discontinued from the regimen from Week 24 up to Week 52.
| Participants | Islatravir 0.25 mg | Islatravir 0.75 mg | Islatravir 2.25 mg | DOR/3TC/TDF |
|---|---|---|---|---|
| Number of Participants Experiencing AEs Through 24 Weeks After 3TC and Placebo Are Discontinued From the Regimen | 18 | 20 | 14 | 16 |
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. 3TC and placebo are discontinued from the regimen from Week 24 up to Week 52.
| Participants | Islatravir 0.25 mg | Islatravir 0.75 mg | Islatravir 2.25 mg | DOR/3TC/TDF |
|---|---|---|---|---|
| Number of Participants Discontinuing Study Drug Due to AEs Through 24 Weeks After 3TC and Placebo Are Discontinued From the Regimen | 0 | 0 | 2 | 1 |
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.
| Participants | Islatravir 0.25 mg | Islatravir 0.75 mg | Islatravir 2.25 mg | DOR/3TC/TDF | DOR/ISL Continued | DOR/ISL Switch |
|---|---|---|---|---|---|---|
| Number of Participants Experiencing AEs From Week 96 Through Study Duration | 12 | 19 | 11 | 12 | 36 | 14 |
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment.
| Participants | Islatravir 0.25 mg | Islatravir 0.75 mg | Islatravir 2.25 mg | DOR/3TC/TDF | DOR/ISL Continued | DOR/ISL Switch |
|---|---|---|---|---|---|---|
| Number of Participants Discontinuing Study Drug Due to AEs From Week 96 Through Study Duration | 1 | 0 | 0 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. The number of participants who experienced AEs during Part 4 are reported.
| Participants | DOR/ISL Continued (Part 4) | DOR/ISL Switch (Part 4) |
|---|---|---|
| Number of Participants Experiencing AEs During Open Label Doravirine/Islatravir Treatment After Week 144 up to Week 192 (Part 4) | 36 | 14 |
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. The number of participants who discontinued the study drug due to AEs in Part 4 are reported.
| Participants | DOR/ISL Continued (Part 4) | DOR/ISL Switch (Part 4) |
|---|---|---|
| Number of Participants Discontinuing Study Drug Due to AEs During Open Label Doravirine/Islatravir Treatment After Week 144 up to Week 192 (Part 4) | 0 | 0 |
Collected over For All-Cause Mortality: from randomization up to 198 weeks. For AEs: from first treatment up to 198 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Islatravir 0.25mg | 0/31 (0%) | 2/29 (6.9%) | 22/29 (75.9%) |
| Islatravir 0.75mg | 0/30 (0%) | 6/30 (20%) | 26/30 (86.7%) |
| Islatravir 2.25mg | 0/31 (0%) | 2/31 (6.5%) | 23/31 (74.2%) |
| DOR/3TC/TDF | 1/31 (3.2%) | 4/31 (12.9%) | 22/31 (71%) |
| DOR/ISL Continued | 0/67 (0%) | 2/67 (3%) | 21/67 (31.3%) |
| DOR/ISL Switch | 0/22 (0%) | 1/22 (4.5%) | 11/22 (50%) |
| Event | Islatravir 0.25mg | Islatravir 0.75mg | Islatravir 2.25mg | DOR/3TC/TDF | DOR/ISL Continued | DOR/ISL Switch |
|---|---|---|---|---|---|---|
| Suicide attemptPsychiatric disorders | 0/29 | 2/30 | 0/31 | 0/31 | 0/67 | 0/22 |
| COVID-19Infections and infestations | 0/29 | 0/30 | 0/31 | 0/31 | 0/67 | 1/22 |
| Atrial fibrillationCardiac disorders | 1/29 | 0/30 | 0/31 | 0/31 | 0/67 | 0/22 |
| Burkitt's lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/29 | 0/30 | 0/31 | 0/31 | 0/67 | 0/22 |
| LymphadenopathyBlood and lymphatic system disorders | 0/29 | 1/30 | 0/31 | 0/31 | 0/67 | 0/22 |
| AppendicitisInfections and infestations | 0/29 | 1/30 | 0/31 | 0/31 | 1/67 | 0/22 |
| Large intestine infectionInfections and infestations | 0/29 | 1/30 | 1/31 | 0/31 | 0/67 | 0/22 |
| Ankle fractureInjury, poisoning and procedural complications | 0/29 | 1/30 | 0/31 | 0/31 | 0/67 | 0/22 |
| Facial paralysisNervous system disorders | 0/29 | 1/30 | 0/31 | 0/31 | 0/67 | 0/22 |
| Alcohol withdrawal syndromePsychiatric disorders | 0/29 | 1/30 | 0/31 | 0/31 | 0/67 | 0/22 |
| Event | Islatravir 0.25mg | Islatravir 0.75mg | Islatravir 2.25mg | DOR/3TC/TDF | DOR/ISL Continued | DOR/ISL Switch |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 2/29 | 9/30 | 2/31 | 7/31 | 0/67 | 1/22 |
| SyphilisInfections and infestations | 6/29 | 8/30 | 2/31 | 6/31 | 4/67 | 1/22 |
| DiarrhoeaGastrointestinal disorders | 1/29 | 6/30 | 3/31 | 8/31 | 0/67 | 3/22 |
| BronchitisInfections and infestations | 2/29 | 7/30 | 1/31 | 5/31 | 0/67 | 0/22 |
| COVID-19Infections and infestations | 0/29 | 3/30 | 1/31 | 1/31 | 2/67 | 5/22 |
| Vitamin D deficiencyMetabolism and nutrition disorders | 1/29 | 6/30 | 4/31 | 2/31 | 0/67 | 0/22 |
| AnxietyPsychiatric disorders | 3/29 | 6/30 | 0/31 | 1/31 | 0/67 | 2/22 |
| HeadacheNervous system disorders | 5/29 | 2/30 | 5/31 | 4/31 | 0/67 | 0/22 |
| NauseaGastrointestinal disorders | 1/29 | 5/30 | 3/31 | 3/31 | 0/67 | 0/22 |
| SinusitisInfections and infestations | 4/29 | 0/30 | 0/31 | 1/31 | 0/67 | 1/22 |
| Age, Continuous(Years) | Islatravir 0.25 mg | Islatravir 0.75 mg | Islatravir 2.25 mg | DOR/3TC/TDF | Total |
|---|---|---|---|---|---|
| Mean | 32.3 ± 13.3 | 30.0 ± 9.0 | 32.4 ± 11.8 | 29.4 ± 8.9 | 31.0 ± 10.9 |
| Sex: Female, Male(Participants) | Islatravir 0.25 mg | Islatravir 0.75 mg | Islatravir 2.25 mg | DOR/3TC/TDF | Total |
|---|---|---|---|---|---|
| Female | 1 | 3 | 3 | 3 | 10 |
| Male | 30 | 27 | 28 | 28 | 113 |
| Ethnicity (NIH/OMB)(Participants) | Islatravir 0.25 mg | Islatravir 0.75 mg | Islatravir 2.25 mg | DOR/3TC/TDF | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 14 | 19 | 12 | 15 | 60 |
| Not Hispanic or Latino | 16 | 11 | 18 | 15 | 60 |
| Unknown or Not Reported | 1 | 0 | 1 | 1 | 3 |
| Race (NIH/OMB)(Participants) | Islatravir 0.25 mg | Islatravir 0.75 mg | Islatravir 2.25 mg | DOR/3TC/TDF | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 6 | 8 | 5 | 25 |
| White | 24 | 24 | 21 | 24 | 93 |
| More than one race | 0 | 0 | 2 | 0 | 2 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 | 2 |
| CD4+ T-Cell Count(cells/mm^3) | Islatravir 0.25 mg | Islatravir 0.75 mg | Islatravir 2.25 mg | DOR/3TC/TDF | Total |
|---|---|---|---|---|---|
| Mean | 450.8 ± 170.0 | 538.5 ± 165.5 | 469.6 ± 203.3 | 508.5 ± 206.8 | 492.1 ± 188.5 |
| Participants with <=100,000 copies/mL of HIV-1 RNA(Participants) | Islatravir 0.25 mg | Islatravir 0.75 mg | Islatravir 2.25 mg | DOR/3TC/TDF | Total |
|---|---|---|---|---|---|
| Count of participants | 24 | 23 | 23 | 24 | 94 |
| Participants with >100,000 copies/mL of HIV-1 RNA(Participants) | Islatravir 0.25 mg | Islatravir 0.75 mg | Islatravir 2.25 mg | DOR/3TC/TDF | Total |
|---|---|---|---|---|---|
| Count of participants | 7 | 7 | 8 | 7 | 29 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Nov 2017 to primary completion in Mar 2021, 39 months.
Results were first posted in Apr 2022, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Islatravir · Doravirine · Lamivudine · Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate